Sucralfate 1 g Tablet, 90-count — NDC 62135-436-90 (Billing 62135-0436-90)
This is a package of 90 tablets of Sucralfate 1 g Tablet from Chartwell RX, LLC, marketed since Feb 2020 and currently FDA-listed; retail pharmacies pay about $0.1727 per tablet (NADAC). It is the main listing for this product, which comes in 2 package sizes.
NDC database record
One package, one record: these facts belong to NDC 62135-436-90 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 62135 labeler · 436 product · 90 package
- Package marketed since
- Nov 4, 2022
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Billing quantity
- 90 EA per package
- Barcode (UPC)
- 0362135436902, 0362135436018
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 002766
- GCN: 08200
- GPI-14 (Medi-Span): 49300010000305
- HICL (First Databank): 001186
- AHFS class code: 56:28.32.00
- RxCUI (RxNorm): 314234
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 5, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Aluminum Complex class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
Sucralfate is used to treat and prevent the return of duodenal ulcers (ulcers located in first part of the small intestine). Treatment with other medications, such as antibiotics, may also be necessary to treat and prevent the return of ulcers caused by a certain type of bacteria (H. pylori) Sucralfate is in a class of medications called protectants. It sticks to damaged ulcer tissue and protects against acid and enzymes so healing can occur.
Read the full MedlinePlus article ↗- It treats an active duodenal ulcer, which is a sore in the first part of your small intestine. Treatment usually lasts up to 8 weeks. The tablets can also be used at a lower dose t...
- Take it by mouth on an empty stomach, as your prescriber directs. For an active ulcer, the label describes four doses a day. Keep going for the full course even if you feel better,...
- Yes, for pain relief if your doctor allows. Just keep them at least 30 minutes before or after your sucralfate dose.
- Constipation is the most common one, though most people have no trouble. Some get nausea, diarrhea, dry mouth, dizziness or a rash. Call your doctor if something bothers you or doe...
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Sucralfate — tap one for details:
Sucralfate may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 5, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.173 | $15.54 / 90 tablets |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file · file of Sep 30, 2026
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 5, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 62135-0436-90 You're viewing this Main listing | 90 TABLET in 1 BOTTLE | $0.1727 / ea | $15.54 | 2022-11-04 | — | Active |
| 62135-0436-01 62135-436-01 | 100 TABLET in 1 BOTTLE | — | — | 2023-03-13 | — | Active |
You're viewing the smallest of 2 pack sizes for this product.
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 62135-0436-01?
What NDC number is used to bill for this package of Sucralfate 1 g Tablet?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Sucralfate 1 g 00093-2210-01 | Teva | 100 tablets | $0.173 | AB | Availability likely | — |
| Sucralfate 1 g 51079-0753-20 | Mylan | 100 tablets | $0.173 | AB | Availability likely | — |
| Sucralfate 1 g 59762-0401-01 | Mylan | 100 tablets | $0.173 | AB | Availability likely | — |
| Sucralfate 1 g 60219-1656-01 | Amneal | 100 tablets | $0.173 | AB | Availability likely | — |
| Sucralfate 1 gthis 62135-0436-90 | Chartwell | 90 tablets | $0.173 | AB | Availability likely | — |
| Sucralfate 1 g 69238-1656-01 | Amneal | 100 tablets | $0.173 | AB | Availability likely | — |
| Sucralfate 1 g 72578-0081-01 | Viona | 100 tablets | $0.173 | AB | Availability likely | — |
| Sucralfate 1 g 60687-0695-01 | American | 100 tablets | $0.179 | AB | Discontinued | +3% |
| Carafate 1 g 58914-0171-10 | Allergan, | 100 tablets | $4.731 | AB | Availability likely | +2639% |
| Sucralfate 1 g 00615-4517-30 | NCS | 30 tablets | — | AB | Discontinued | — |
| Sucralfate 1 g 00615-8653-39 | NCS | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 42291-0936-90 | AvKARE | 90 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 48433-0091-20 | Safecor | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 50090-5287-00 | A-S | 60 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 50090-6455-00 | A-S | 60 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 51407-0881-90 | Golden | 90 tablets | — | AB | Discontinued | — |
| Sucralfate 1 g 51655-0031-52 | Northwind | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 51655-0475-52 | Northwind | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 55154-4379-00 | Cardinal | 10 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 63629-1307-00 | Bryant | 28 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 63629-9152-01 | Bryant | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 63629-9153-01 | Bryant | 500 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 67046-1469-03 | Coupler | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 67296-2147-04 | Redpharm | 40 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68071-1749-01 | NuCare | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68071-3478-03 | NuCare | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68071-3812-03 | NuCare | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68788-8316-01 | Preferred | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68788-8779-03 | Preferred | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 68788-8946-01 | Preferred | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 70771-1833-01 | Zydus | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 71335-2114-00 | Bryant | 28 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 71335-2461-00 | Bryant | 28 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 71335-2637-00 | Bryant | 28 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 71610-0017-60 | Aphena | 90 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 71610-0541-60 | Aphena | 90 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 72162-2264-01 | Bryant | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 72189-0234-20 | DIRECT | 20 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 72189-0429-20 | Direct_Rx | 20 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 80425-0091-01 | Advanced | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 80425-0188-01 | Advanced | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 80425-0213-01 | Advanced | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 80425-0377-01 | Advanced | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 82804-0063-30 | Proficient | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 82804-0102-30 | Proficient | 30 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 87063-0176-01 | ASCLEMED | 100 tablets | — | AB | FDA listed | — |
| Sucralfate 1 g 55154-0281-00 | Cardinal | 10 tablets | — | AB | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file · file of Sep 30, 2026
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Oct 5, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Sucralfate inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
-
UNII FZ989GH94E
Povidone is a synthetic polymer made from a plastic-like material. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in your stomach so the medicine can be absorbed.
-
UNII ETJ7Z6XBU4
Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
3 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 5, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Chartwell RX, LLC labeler code 62135
- Ursodiol 300 mg Capsule NDC 62135-430-60
- Disulfiram 250 mg Tablet NDC 62135-431-30
- Disulfiram 500 mg Tablet NDC 62135-432-30
- butalbital, aspirin, and caffeine 50 mg; 325 mg; 40 mg Capsule NDC 62135-433-90
- Sodium Citrate and Citric Acid 500 mg/5mL; 334 mg/5mL Solution NDC 62135-434-47
- Potassium Citrate and Citric Acid 1100 mg/5mL; 334 mg/5mL Solution NDC 62135-435-24
- Prednisolone 5 mg Tablet NDC 62135-437-30
- Tricitrates 550 mg/5mL; 500 mg/5mL; 334 mg/5mL Solution NDC 62135-438-24
- Ergocalciferol 1.25 mg Capsule NDC 62135-439-90
- Benzonatate 100 mg Capsule NDC 62135-440-01
- Benzonatate 200 mg Capsule NDC 62135-441-31
- linezolid 600 mg Tablet NDC 62135-442-20
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Sucralfate tablets are indicated in: Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Active Duodenal Ulcer. The recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach. Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.
While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance Therapy: The recommended adult oral dosage is 1 g twice a day. Elderly: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (See PRECAUTIONS, Geriatric Use ).
Call your doctor for medical advice about side effects. You may report side effects to Chartwell RX, LLC. at 845-232-1683 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
⛔ Contraindications ▾
CONTRAINDICATIONS Sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Adverse reactions to sucralfate in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2700 patients treated with sucralfate tablets, adverse effects were reported in 129 (4.7%). Constipation was the most frequent complaint (2%).
Other adverse effects reported in less than 0.5% of the patients are listed below by body system: Gastrointestinal: diarrhea, nausea, vomiting, gastric discomfort, indigestion, flatulence, dry mouth Dermatological: pruritus, rash Nervous System: dizziness, insomnia, sleepiness, vertigo Other: back pain, headache Post-marketing: cases of hypersensitivity have been reported with the use of sucralfate tablets, including dyspnea, lip swelling, pruritus, rash, and urticaria. Cases of anaphylactic reactions, bronchospasm, laryngeal edema, edema of the mouth, pharyngeal edema, respiratory tract edema and swelling of the face have been reported with an unknown oral formulation of sucralfate.
Bezoars have been reported in patients treated with sucralfate. The majority of patients had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings. Inadvertent injection of insoluble sucralfate and its insoluble excipients has led to fatal complications, including pulmonary and cerebral emboli.
Sucralfate is not intended for intravenous administration.
🆘 Overdosage ▾
OVERDOSAGE Due to limited experience in humans with overdosage of sucralfate, no specific treatment recommendations can be given. Acute oral toxicity studies in animals, however, using doses up to 12 g/kg body weight, could not find a lethal dose. Sucralfate is only minimally absorbed from the gastrointestinal tract.
Risks associated with acute overdosage should, therefore, be minimal. In rare reports describing sucralfate overdose, most patients remained asymptomatic. Those few reports where adverse events were described included symptoms of dyspepsia, abdominal pain, nausea, and vomiting.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. Although the mechanism of sucralfate’s ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action.
The following observations also appear pertinent: Studies in human subjects and with animal models of ulcer disease have shown that sucralfate forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site. In vitro , a sucralfate-albumin film provides a barrier to diffusion of hydrogen ions. In human subjects, sucralfate given in doses recommended for ulcer therapy inhibits pepsin activity in gastric juice by 32%.
In vitro , sucralfate adsorbs bile salts. These observations suggest that sucralfate’s antiulcer activity is the result of formation of an ulcer adherent complex that covers the ulcer site and protects it against further attack by acid, pepsin, and bile salts. There are approximately 14 to 16 mEq of acid-neutralizing capacity per 1 g dose of sucralfate.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Sucralfate 1 g tablets, USP are supplied in bottles of 90 and 100. White, oblong, bisected tablets debossed with "N'' and ''S1'' on one side. Bottles of 90...........NDC 62135-436-90 Bottles of 100...........NDC 62135-436-01 Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Manufactured for: Chartwell RX, LLC. Congers, NY 10920 L71148 Rev. 11/2022 Rx Only
📋 Description ▾
DESCRIPTION Sucralfate is an α-D-glucopyranoside, β-D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. It has the following structural formula: Tablets for oral administration contain 1 g of sucralfate, USP. Also contain: povidone, magnesium stearate, and colloidal silicon dioxide. Therapeutic category: antiulcer. image description
⚠️ Precautions ▾
PRECAUTIONS The physician should read the "PRECAUTIONS" section when considering the use of this drug in pregnant or pediatric patients, or patients of childbearing potential. Duodenal ulcer is a chronic, recurrent disease. While short-term treatment with sucralfate can result in complete healing of the ulcer, a successful course of treatment with sucralfate should not be expected to alter the post healing frequency or severity of duodenal ulceration.
Isolated reports of sucralfate tablet aspiration with accompanying respiratory complications have been received. Therefore, sucralfate tablets should be used with caution by patients who have known conditions that may impair swallowing, such as recent or prolonged intubation, tracheostomy, prior history of aspiration, dysphagia, or any other conditions that may alter gag and cough reflexes, or diminish oropharyngeal coordination or motility.
📄 Package Label / Principal Display Panel ▾
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Sucralfate Tablet, USP 1 Gram - NDC-62135-436-90 - 90's-Bottle Label Sucralfate Tablet, USP 1 Gram - NDC-62135-436-01 - 100's-Bottle Label Sucralfate Tablet, USP 1 Gram - NDC-62135-436-90 - 90's-Bottle Label image description